ストックスクリーナーアプリを入手
4.71
3.58%
-0.175
アフターアワーズ：
4.71
前日終値:
$4.885
開ける：
$4.87
24時間の取引高:
16.89M
Relative Volume:
0.41
時価総額：
$2.45B
収益：
$64.60M
当期純損益:
$-377.75M
株価収益率:
-3.0387
EPS:
-1.55
ネットキャッシュフロー:
$-335.64M
1週間 パフォーマンス:
+1.73%
1か月 パフォーマンス:
-5.04%
6か月 パフォーマンス:
+3.06%
1年 パフォーマンス:
-28.53%
1日の値動き範囲:
$4.67
$4.88
1週間の範囲:
$4.31
$4.94
52週間の値動き範囲:
$3.79
$12.36
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
名前
Recursion Pharmaceuticals Inc
セクター
電話
(385) 269-0203
住所
41S RIO GRANDE STREET, SALT LAKE CITY
RXRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
4.71 | 2.56B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.48 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.36 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.12 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
901.17 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.00 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-03 | 再開されました | Morgan Stanley | Equal-Weight |
| 2023-05-22 | 開始されました | Morgan Stanley | Equal-Weight |
| 2023-03-16 | 開始されました | Needham | Buy |
| 2022-09-16 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-03-04 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | 開始されました | Berenberg | Buy |
| 2021-05-11 | 開始されました | BofA Securities | Buy |
| 2021-05-11 | 開始されました | Goldman | Neutral |
| 2021-05-11 | 開始されました | JP Morgan | Neutral |
| 2021-05-11 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Recursion Pharmaceuticals Inc (RXRX) 最新ニュース
Growth Value: Can Recursion Pharmaceuticals Inc stock maintain growth trajectoryQuarterly Portfolio Report & AI Enhanced Trading Alerts - BỘ NỘI VỤ
Recursion pharma CEO Gibson sells $185,200 in shares - Investing.com
Insider Selling: Recursion Pharmaceuticals (NASDAQ:RXRX) Director Sells 220,000 Shares of Stock - MarketBeat
Recursion Pharmaceuticals (RXRX) Up 6.5% Since Last Earnings Report: Can It Continue? - sharewise.com
Jim Cramer: This Health Care Stock Has Been 'Horrendous' - Benzinga
Recursion Pharmaceuticals Registers Resale of 7 Million Shares - MSN
Recursion Pharmaceuticals: Is It the Right Time to Buy? - StocksToTrade
Cramer's Lightning Round: Recursion Pharmaceuticals 'has been horrendous' - CNBC
Recursion Pharmaceuticals Insider Sold Shares Worth $961,400, According to a Recent SEC Filing - marketscreener.com
Recursion Pharmaceuticals: Is This Just The Beginning? - timothysykes.com
A Look At The Fair Value Of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - 富途牛牛
RECURSION PHARMACEUTICALS INC (RXRX.MX) Q1 FY2025 earnings call transcript - Yahoo Finance
Recursion Pharmaceuticals Stock (RXRX) Opinions on Exscientia Merger and Clinical Data Readout - Quiver Quantitative
Miss These Genesis Mission Stocks, and You’ll Regret It for a Decade - InvestorPlace
Costco, AMD, Recursion Pharmaceuticals, Cipher Mining And Snowflake: Why These 5 Stocks Are On Investors' Radars Today - AOL.com
Capital Fund Management S.A. Has $3.65 Million Stock Holdings in Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Can Recursion Pharmaceuticals Inc. stock continue upward trendQuarterly Profit Report & Advanced Swing Trade Entry Alerts - Newser
Is Recursion Pharmaceuticals Inc. stock attractive for hedge fundsMarket Trend Review & Verified Technical Signals - Newser
Quadrature Capital Ltd Takes Position in Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Recursion to Host Webinar on Tupelo Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis on Dec. 8 - TradingView
Recursion to present updated FAP trial data of REC-4881 in webinar - Investing.com Australia
Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025 - The Manila Times
Recursion to Present Updated Clinical Readout from TUPELO Trial of REC-4881 in Familial Adenomatous Polyposis at December 8 Webinar - Quiver Quantitative
Recursion Pharmaceuticals (RXRX): Valuation Insights Following New Partnerships and Better-Than-Expected Quarterly Results - Sahm
Will Recursion (RXRX) Share Registration Deepen Its Tech Partnerships or Signal a Shift in Strategy? - simplywall.st
Recursion Pharmaceuticals Gains Traction with Strategic Developments - timothysykes.com
Recursion Pharmaceuticals’ Advances Boost Market Confidence - timothysykes.com
Tangible book value per share of Recursion Pharmaceuticals, Inc. Class A – BIVA:RXRX - TradingView
Geode Capital Management LLC Acquires 1,332,428 Shares of Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
XTX Topco Ltd Buys New Shares in Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Forget Recursion Pharmaceuticals: This Could Be an Even Better Artificial Intelligence (AI) Stock - AOL.com
Rockefeller Capital Management L.P. Sells 170,691 Shares of Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
RXRX SEC FilingsRecursion Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
CFO Taylor Surrenders 2,271 Of Recursion Pharmaceuticals Inc [RXRX] - TradingView
[Form 4] RECURSION PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Recursion Pharmaceuticals Stock (RXRX) Opinions on Exscientia Merger and Partnerships - Quiver Quantitative
Recursion Pharmaceuticals registers 7.1 million shares for Tempus AI resale By Investing.com - Investing.com Nigeria
Recursion Pharmaceuticals registers 7.1 million shares for Tempus AI resale - Investing.com
Recursion Pharmaceuticals Registers Resale of Tempus Shares - TradingView
[8-K] RECURSION PHARMACEUTICALS, INC. Reports Material Event | RXRX SEC FilingForm 8-K - Stock Titan
Form 424B7 RECURSION PHARMACEUTICAL - StreetInsider
RXRX files prospectus for Tempus AI resale of 7.09M shares - Stock Titan
Is the Market Bullish or Bearish on Recursion Pharmaceuticals Inc? - Benzinga
A Look at Recursion Pharmaceuticals’s Valuation Following New CEO, Narrowed Losses, and Milestone Partnership Payment - Yahoo Finance
Why Skyrocketed Recursion Pharmaceuticals, Inc. (RXRX) Today - MSN
Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock? - The Globe and Mail
Recursion Pharmaceuticals (RXRX): Evaluating Valuation After Fresh Leadership, Pharma Partnerships, and Market Optimism - simplywall.st
Recursion Pharmaceuticals (RXRX) Stock Today: ‘Hold’ Rating, New Institutional Buying and AI Drug Discovery Hype — November 23, 2025 - ts2.tech
Top Biotech Stocks To Watch TodayNovember 21st - MarketBeat
Recursion (RXRX) Jumps 8% on Bargain-Hunting - Finviz
Recursion Pharmaceuticals Inc (RXRX) 財務データ
収益
当期純利益
現金流量
EPS
1.44%
0.91%
大文字化:
|
ボリューム (24 時間):